Results 101 to 110 of about 216,339 (397)

BEV-IP : perioperative chemotherapy with bevacizumab in patients undergoing cytoreduction and intraperitoneal chemoperfusion for colorectal carcinomatosis [PDF]

, 2015
Background: Selected patients with peritoneal carcinomatosis (PC) from colorectal cancer (CRC) benefit from cytoreductive surgery (CRS) combined with intraperitoneal chemoperfusion (IPC).
Ceelen, Wim, Liberale, Gabriel, Van Der Speeten, Kurt, Willaert, Wouter   +3 more
core   +2 more sources

Deacetylation of ACLY Mediates RNA M6A‐Modification of NOXA and Promotes Chemoresistance of Colorectal Cancer

Advanced Science, EarlyView.
This study investigates the deacetylation of ACLY at K978 acts as a novel risk in colorectal cancer chemoresistance. The deacetylation of K978 induces ACLY relocation to the nucleus and promotes its binding to RBM15, a m6A methylation modification “writer”.
Jun Wen, Mengqin Shen, Haitao Zhao, Liu Liu, Qian Hua, Xiaoping Zhao, Jianjun Liu, Haizhong Feng, Gang Huang   +8 more
wiley   +1 more source

A Single Institution's Experience with Bevacizumab in Combination with Cytotoxic Chemotherapy in Progressive Malignant Glioma

Clinical Medicine Insights: Oncology, 2008
Background Bevacizumab and irinotecan may represent one of the most active treatments in progressive malignant glioma. Limited published experience with bevacizumab in patients with CNS tumors raises concerns regarding toxicity, particularly in regards ...
Tina Mayer, Jill Lacy, Joachim Baehring M.D.   +2 more
doaj   +1 more source

CENTRAL MACULAR THICKNESS AFTER COMBINED THERAPY OF BEVACIZUMAB INTRAVITREAL INJECTION AND TOPICAL DICLOFENAC COMPARED WITH BEVACIZUMAB INTRAVITREAL INJECTION ALONE IN DIABETIC MACULAR EDEMA

IJRETINA (International Journal of Retina), 2021
Introduction: To evaluate whether the combination of diclofenac eye drops and bevacizumab intravitreal injection would provide additional benefits over bevacizumab alone in the treatment of naïve diabetic macular edema (DME).
Melvina Nidya Sandra, Yumni Shabrina, Tri Wahyu Widayanti, Retno Ekantini, Agus Supartoto, Muhammad Bayu Sasongko, Supanji Haryanto   +6 more
doaj   +1 more source

ASH2L‐K312‐Lac Stimulates Angiogenesis in Tumors to Expedite the Malignant Progression of Hepatocellular Carcinoma

Advanced Science, EarlyView.
In this study, ASH2L‐K312‐lac is identified as a critical driver that promotes the malignant progression of hepatocellular carcinoma (HCC). Furthermore, through a comprehensive series of cell biological and molecular biological experiments, integrated with diverse animal models and systematic application of high‐throughput sequencing technologies, it ...
Hexu Han, Shuai Wang, Lixing Ma, Haimeng Yin, Xinxiang Cheng, YiFan Wang, Suqin Xia, Yi Zhang, Yue Zhang, Rong Zhu, Cuixia Liu, Dakun Zhao, Xiangqian Gu, He Zhu, Yin Yuan   +14 more
wiley   +1 more source

Hepatic Events and Viral Kinetics in Hepatocellular Carcinoma Patients Treated With Atezolizumab Plus Bevacizumab

Liver Cancer, 2022
Introduction: In the Phase 3 IMbrave150 trial (NCT03434379), atezolizumab + bevacizumab demonstrated a clinically meaningful survival benefit over sorafenib in patients with unresectable hepatocellular carcinoma (HCC), including those with hepatitis B ...
Chiun Hsu, Michel Ducreux, Andrew X. Zhu, Shukui Qin, Masafumi Ikeda, Tae-You Kim, Peter R. Galle, Richard S. Finn, Ethan Chen, Ning Ma, Youyou Hu, Lindong Li, Ann-Lii Cheng   +12 more
doaj   +1 more source

Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma

Clinical Cancer Research, 2020
Purpose: VEGF is upregulated in glioblastoma and may contribute to immunosuppression. We performed a phase II study of pembrolizumab alone or with bevacizumab in recurrent glioblastoma.
L. Nayak, A. Molinaro, K. Peters, Jennifer L. Clarke, J. Jordan, J. D. de Groot, L. Nghiemphu, T. Kaley, H. Colman, Christine McCluskey, Sarah C. Gaffey, T. Smith, D. Cote, Mariano Severgnini, J. Yearley, Qing Zhao, W. Blumenschein, D. Duda, A. Muzikansky, R. Jain, P. Wen, D. Reardon   +21 more
semanticscholar   +1 more source

Tumor angiogenesis and anti-angiogenic therapy in malignant gliomas revisited [PDF]

, 2012
The cellular and molecular mechanisms of tumor angiogenesis and its prospects for anti-angiogenic cancer therapy are major issues in almost all current concepts of both cancer biology and targeted cancer therapy. Currently, (1) sprouting angiogenesis, (2)
Dumont, Daniel J., Plate, Karl H., Scholz, Alexander   +2 more
core   +1 more source

Hypoxia‐Induced PRMT1 Lactylation Drives Vimentin Arginine Asymmetric Dimethylation in Tumor Metastasis

Advanced Science, EarlyView.
Hypoxia triggers lactylation of PRMT1 at K134/K145, enhancing its methyltransferase activity to asymmetrically dimethylate vimentin R64. This post‐translational cascade promotes vimentin filament assembly, cytoskeletal remodeling, and tumor metastasis, with PRMT1 inhibition (MS023) reducing metastatic colonization.
Jia Zhou, Shuying Qiu, Xia Yang, Yan Wu, Xinxia Yao, Hangqi Hu, Jingfeng Luo, Chandra Sugiarto Wijaya, Lingfeng Ma, Xiaojun Long, Lingna Xu, Jinquan Liu, Chaoqun Wang, Yibin Pan, Xiaona Chen, Hongchuan Jin, Xian Wang   +16 more
wiley   +1 more source

The addition of bevacizumab to standard chemotherapy in breast cancer : which patient benefits the most? [PDF]

, 2013
Bevacizumab, a humanized monoclonal antibody directed against vascular endothelial growth factor, is an effective and well-tolerated treatment option for patients with breast cancer.
Cocquyt, Veronique, Denys, Hannelore, KRUSE, VIBEKE, Van Belle, Simon, Van den Broecke, Rudy   +4 more
core   +2 more sources